Back to results
US 11,439,670 B2Granted
Akkermansia muciniphila EB-AMDK27 strain and use thereof
AssigneeEnterobiome Inc.
InventorsJae-Gu Seo, Joo-Hyun Shin, Do-Kyung Lee
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeEnterobiome Inc.
InventorsJae-Gu Seo, Joo-Hyun Shin, Do-Kyung Lee
Estimating the term…
Disclosed are a novel Akkermansia muciniphila EB-AMDK27 strain having the effect of preventing or treating inflammatory disease or metabolic disease, and a pharmaceutical composition effective for preventing or treating inflammatory disease or metabolic disease, which contains the strain, a culture thereof, or a dried product thereof. While traditional probiotics generally have insufficient therapeutic effects on inflammatory or metabolic diseases, the disclosed next generation probiotic strain has an excellent effect on the prevention or treatment of inflammatory disease and/or metabolic disease so that it may be used as a new prophylactic and therapeutic tool.
A pharmaceutical composition comprising an isolated Akkermansia muciniphila EB-AMDK27 strain (accession number KCTC 13758BP), a culture thereof, or a dried product thereof;
A food comprising an isolated Akkermansia muciniphila EB-AMDK27 strain (accession number KCTC 13758BP), a culture thereof, or a dried product thereof and a carrier or an excipient, wherein the Akkermansia muciniphila EB-AMDK27 strain is lyophilized and/or enteric coated.
A method selected from the following (a)-(f), said method comprising administering to a subject in need thereof an effective amount of a composition which comprises, as an active ingredient, an isolated Akkermansia muciniphila EB-AMDK27 strain (accession number KCTC 13758BP), a culture thereof, a dried powder of the isolated strain, or a dried powder of the culture,
Dependencies are inferred from the claim text.